Your browser is no longer supported. Please, upgrade your browser.
Settings
CLDX Celldex Therapeutics, Inc. daily Stock Chart
CLDX [NASD]
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-17.46 Insider Own0.10% Shs Outstand10.14M Perf Week13.43%
Market Cap57.39M Forward P/E- EPS next Y-6.00 Insider Trans394.48% Shs Float10.14M Perf Month10.49%
Income-164.70M PEG- EPS next Q-1.20 Inst Own27.50% Short Float21.17% Perf Quarter11.97%
Sales11.20M P/S5.12 EPS this Y31.10% Inst Trans-6.10% Short Ratio7.01 Perf Half Y-10.31%
Book/sh11.74 P/B0.48 EPS next Y60.00% ROA-68.20% Target Price32.25 Perf Year-83.94%
Cash/sh10.41 P/C0.54 EPS next 5Y- ROE-93.00% 52W Range2.74 - 42.90 Perf YTD90.67%
Dividend- P/FCF- EPS past 5Y3.20% ROI-49.20% 52W High-86.81% Beta4.43
Dividend %- Quick Ratio6.60 Sales past 5Y2.60% Gross Margin- 52W Low106.19% ATR1.11
Employees192 Current Ratio6.60 Sales Q/Q-76.90% Oper. Margin- RSI (14)49.70 Volatility13.43% 22.60%
OptionableYes Debt/Eq0.00 EPS Q/Q78.20% Profit Margin- Rel Volume1.40 Prev Close5.66
ShortableNo LT Debt/Eq0.00 EarningsMar 06 AMC Payout- Avg Volume306.06K Price5.66
Recom2.00 SMA20-10.31% SMA5018.69% SMA200-13.83% Volume0 Change0.00%
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Feb-20-19 08:25AM  Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-14-19 10:45AM  The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna Zacks -6.51%
Feb-13-19 08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks +10.82%
Feb-11-19 12:26PM  The Celldex Reverse Stock Split: What Investors Need To Know Benzinga -19.03%
09:55AM  Biotech Stocks To Watch ACCESSWIRE
Feb-08-19 11:45AM  Celldex Therapeutics Announces Reverse Stock Split GlobeNewswire -31.17%
Feb-05-19 09:20AM  4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19) ACCESSWIRE -16.04%
08:30AM  Biotech Stocks to Watch ACCESSWIRE
Feb-04-19 02:35PM  These 4 Tech Stocks Could Set February Highs ACCESSWIRE +19.35%
Jan-29-19 08:30AM  Cannabis and Biotech Stocks that Could Explode ACCESSWIRE
Jan-23-19 08:30AM  Best Ways to Play Biotech Rally ACCESSWIRE
Jan-21-19 08:30AM  A Biotech Play You Can't Afford To Miss ACCESSWIRE
Dec-21-18 08:15PM  Here's Why Celldex Therapeutics Sank on Friday Motley Fool -13.08%
Dec-10-18 12:24PM  Why Celldex Therapeutics Is Jumping Today Motley Fool +6.61%
Nov-26-18 08:35AM  Analysis: Positioning to Benefit within Celldex Therapeutics, InnSuites Hospitality Trust, Keryx Biopharmaceuticals, EMX Royalty, FTE Networks, and Xinyuan Real Estate Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-10-18 08:01AM  Celldex Presents Emerging MerTK Antibody Program at the Society for Immunotherapy of Cancers 33rd Annual Meeting GlobeNewswire
Nov-09-18 08:12AM  Celldex (CLDX) Q3 Earnings Beat Estimates, Revenues Miss Zacks
08:01AM  Celldex Presents Promising Interim Data from Phase 1 Study of Differentiated CD40 Agonist CDX-1140 at the Society for Immunotherapy of Cancers 33rd Annual Meeting GlobeNewswire
Nov-08-18 05:48PM  Here's Why Celldex Therapeutics, Inc. Surged on Thursday Motley Fool +12.79%
08:45AM  Celldex Therapeutics Inc. Chugs Along in the 3rd Quarter Despite Challenges Motley Fool
Nov-07-18 06:55PM  Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:49PM  Celldex: 3Q Earnings Snapshot Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Third Quarter 2018 Results GlobeNewswire
Nov-01-18 03:51PM  Why Shares of Celldex Therapeutics, Inc. Sailed Higher Today Motley Fool +10.02%
Oct-22-18 03:18PM  Why Celldex Therapeutics, Inc. Fell on Monday Motley Fool -10.60%
Oct-09-18 07:50AM  Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global Future Expectations, Projections Moving into 2018 GlobeNewswire
Sep-18-18 09:04AM  What Investors Should Know About Celldex Therapeutics Incs (NASDAQ:CLDX) Financial Strength Simply Wall St.
Sep-07-18 09:30AM  Why Is Celldex (CLDX) Up 3.3% Since Last Earnings Report? Zacks
Aug-23-18 03:03PM  Why Celldex Therapeutics Inc. Shares Jumped on Wednesday Motley Fool -5.52%
08:00AM  Today's Research Reports on Trending Tickers: Celldex Therapeutics and Inovio Pharmaceuticals ACCESSWIRE
Aug-09-18 10:04AM  Celldex (CLDX) Q2 Earnings and Revenues Surpass Estimates Zacks -6.76%
06:30AM  Celldex Therapeutics, Inc. Spending Cuts Help Preserve Cash in the 2nd Quarter Motley Fool
Aug-08-18 07:50PM  Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates Zacks +5.18%
06:44PM  Celldex: 2Q Earnings Snapshot Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Second Quarter 2018 Results GlobeNewswire
02:30PM  Celldex Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-02-18 08:01AM  Celldex to Report Second Quarter 2018 Financial Results and Host Corporate Update Call GlobeNewswire
Aug-01-18 07:45AM  Research Report Identifies Myriad Genetics, Celldex Therapeutics, Charles River Laboratories International, Louisiana-Pacific, Integrated Device Technology, and Beazer Homes with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -5.48%
Jul-30-18 09:55AM  What's in Store for Celldex (CLDX) This Earnings Season? Zacks
Jul-27-18 07:35AM  Initiating Free Research Reports on Celgene and Three Other Biotech Equities ACCESSWIRE -5.89%
Jul-02-18 02:18PM  How David Gardner's Biggest Losers Demonstrate Why Long-Term Investing Wins Motley Fool
Jun-29-18 08:17AM  Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics Motley Fool
Jun-21-18 08:00AM  Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks ACCESSWIRE
Jun-11-18 06:32AM  Celldex Therapeutics (CLDX) Down 9.2% Since Earnings Report: Can It Rebound? Zacks
Jun-02-18 04:12PM  Celldex Presents Promising Data from Phase 1/2 Study of Varlilumab and Opdivo® at 2018 ASCO Annual Meeting GlobeNewswire
Jun-01-18 11:30AM  Celldex Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-18-18 07:05AM  Audentes Therapeutics and Three More Stocks Under Scanner in the Biotech Space ACCESSWIRE
May-16-18 05:01PM  Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-15-18 02:43PM  May Insights Into Healthcare Stocks: Celldex Therapeutics Inc (NASDAQ:CLDX) Simply Wall St.
May-11-18 09:59AM  Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down Zacks
May-10-18 03:16PM  Celldex Therapeutics Moves Forward After Glemba Clinical Failure Motley Fool -6.48%
09:00AM  Celldex (CLDX) Q1 Loss Narrower, Revenues Beat, Shares Down Zacks
08:41AM  Celldex: 1Q Earnings Snapshot Associated Press
08:00AM  Celldex Provides Corporate Update and Reports First Quarter 2018 Results GlobeNewswire
May-03-18 10:24AM  What's in Store for Celldex (CLDX) This Earnings Season? Zacks
Apr-25-18 10:33AM  Lessons to Learn From April's Biotech Blowups Motley Fool
Apr-23-18 11:20AM  Is It Game Over for Celldex? Motley Fool
Apr-22-18 10:50AM  Johnson & Johnson's First-Quarter 2018 Earnings Review Motley Fool
Apr-20-18 08:01AM  Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018 GlobeNewswire
07:55AM  Analysis: Positioning to Benefit within Celldex Therapeutics, McDermott International, Briggs & Stratton, Tile Shop Hldgs, Essendant, and Anworth Mortgage Asset Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Apr-18-18 10:07AM  Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics Zacks -8.10%
Apr-17-18 09:55AM  Celldex's Phase II Breast Cancer Study Fails, Shares Plunge Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Celldex Therapeutics and Cancer Genetics ACCESSWIRE
Apr-16-18 08:50AM  Why Celldex Therapeutics Stock Is Cratering Today Motley Fool -64.60%
07:45AM  Celldex's stock plummets toward record low after failed drug study MarketWatch
07:00AM  Celldexs METRIC Study in Metastatic Triple-negative Breast Cancer Does Not Meet Primary Endpoint GlobeNewswire
Apr-10-18 08:46AM  Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options Zacks
Apr-03-18 04:15PM  Celldex Therapeutics Inc (NASDAQ:CLDX): Has Recent Earnings Growth Beaten Long-Term Trend? Simply Wall St.
06:33AM  3 Top Small-Cap Biotech Stocks for Aggressive Investors Motley Fool
Mar-26-18 05:58PM  Celldex Therapeutics Inc (NASDAQ:CLDX): Are Analysts Optimistic? Simply Wall St.
Mar-16-18 04:14PM  What Do Analysts Think About Celldex Therapeutics Incs (NASDAQ:CLDX) Future? Simply Wall St.
Mar-13-18 06:33AM  Why Celldex Therapeutics Stock Crashed in February Motley Fool -8.51%
06:32AM  Is Celldex Therapeutics Stock About to Skyrocket? Motley Fool
Mar-12-18 04:17PM  3 Top Healthcare Stocks to Buy in March Motley Fool
Mar-09-18 04:21PM  Edited Transcript of CLDX earnings conference call or presentation 7-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
07:31AM  Celldex Therapeutics: Make-or-Break-It Data Expected Soon Motley Fool
Mar-08-18 04:40PM  Why Celldex Therapeutics Shot Up Today Motley Fool +11.34%
10:51AM  Celldex (CLDX) Q4 Loss Narrows, Revenues Beat, Shares Up Zacks
10:33AM  Celldex Therapeutics Finishes 2017 With Plenty of Cash and High Hopes Motley Fool
08:20AM  Todays Research Reports on Trending Tickers: Celldex Therapeutics, Inc. and Geron Corporation ACCESSWIRE
Mar-07-18 04:47PM  Celldex reports 4Q loss Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Full Year 2017 Results GlobeNewswire
12:30PM  Celldex Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-18 11:11AM  What's in the Cards for Merck KGaA (MKGAF) in Q4 Earnings? Zacks
09:35AM  What's in Store for Catalyst (CPRX) This Earnings Season? Zacks
Mar-02-18 03:15PM  Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference GlobeNewswire
Mar-01-18 04:30PM  Is a Beat in the Cards for Celldex (CLDX) in Q4 Earnings? Zacks
Feb-16-18 07:17AM  3 Stocks That Could Put Tesla's Returns to Shame Motley Fool
Feb-15-18 08:25AM  Investor Expectations to Drive Momentum within Workday, The Medicines, Celldex Therapeutics, Lannett, Oclaro, and Antares Pharma Discovering Underlying Factors of Influence GlobeNewswire
Jan-31-18 07:31AM  Is Celldex Therapeutics, Inc. (CLDX) a Buy? Motley Fool
Jan-27-18 09:31AM  What to Expect From Celldex Therapeutics, Inc. in 2018 Motley Fool
Jan-21-18 11:00AM  3 Growth Stocks That Could Put Shopify's Returns to Shame Motley Fool
Jan-16-18 08:30AM  Will 2018 Be Celldex Therapeutics, Inc.'s Best Year Yet? Motley Fool
Jan-09-18 04:37PM  AbbVie's Upadacitinib Gains Breakthrough Therapy Designation Zacks
10:42AM  Amgen Announces Acceptance of MAA for Evenity in Europe Zacks
Jan-08-18 05:54PM  Ultragenyx Announces Interim Data from Early Stage Study Zacks
Jan-03-18 07:29AM  3 Biotech Stocks to Buy in January Motley Fool
Jan-02-18 08:57AM  4 Reasons to Include Celldex (CLDX) Stock in Your Portfolio Zacks
Dec-29-17 09:55AM  TherapeuticsMD Submits NDA for VMS Candidate, Shares Rise Zacks
Dec-21-17 09:53AM  AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study Zacks
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma. The company also develops earlier stage drug candidates that are in clinical development, including CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers; CDX-1140, a human monoclonal antibody; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-1401, an immunotherapeutic aimed at antigen presenting cells for cancer indications. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; Seattle Genetics, Inc.; Yale University; and MedImmune, LLC. The company is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARINO JAMES JDirectorAug 24Buy0.4840,00019,20065,997Aug 28 07:34 AM
KELER TIBORExecutive VP & CSOJun 15Buy0.5916,5009,78335,368Jun 18 08:15 AM